These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 25933096

  • 1. OXPHOS-Mediated Induction of NAD+ Promotes Complete Oxidation of Fatty Acids and Interdicts Non-Alcoholic Fatty Liver Disease.
    Akie TE, Liu L, Nam M, Lei S, Cooper MP.
    PLoS One; 2015; 10(5):e0125617. PubMed ID: 25933096
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Chaperonin counteracts diet-induced non-alcoholic fatty liver disease by aiding sirtuin 3 in the control of fatty acid oxidation.
    Weng SW, Wu JC, Shen FC, Chang YH, Su YJ, Lian WS, Tai MH, Su CH, Chuang JH, Lin TK, Liou CW, Chu TH, Kao YH, Wang FS, Wang PW.
    Diabetologia; 2023 May; 66(5):913-930. PubMed ID: 36692509
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling.
    Zeng X, Yang J, Hu O, Huang J, Ran L, Chen M, Zhang Y, Zhou X, Zhu J, Zhang Q, Yi L, Mi M.
    Antioxid Redox Signal; 2019 Jan 10; 30(2):163-183. PubMed ID: 29310441
    [Abstract] [Full Text] [Related]

  • 7. MicroRNA-185 regulates expression of lipid metabolism genes and improves insulin sensitivity in mice with non-alcoholic fatty liver disease.
    Wang XC, Zhan XR, Li XY, Yu JJ, Liu XM.
    World J Gastroenterol; 2014 Dec 21; 20(47):17914-23. PubMed ID: 25548489
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. HCBP6 deficiency exacerbates glucose and lipid metabolism disorders in non-alcoholic fatty liver mice.
    Lu H, Yuan X, Zhang Y, Han M, Liu S, Han K, Liang P, Cheng J.
    Biomed Pharmacother; 2020 Sep 21; 129():110347. PubMed ID: 32535386
    [Abstract] [Full Text] [Related]

  • 11. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease.
    Gariani K, Ryu D, Menzies KJ, Yi HS, Stein S, Zhang H, Perino A, Lemos V, Katsyuba E, Jha P, Vijgen S, Rubbia-Brandt L, Kim YK, Kim JT, Kim KS, Shong M, Schoonjans K, Auwerx J.
    J Hepatol; 2017 Jan 21; 66(1):132-141. PubMed ID: 27663419
    [Abstract] [Full Text] [Related]

  • 12. Geranylgeranyl diphosphate synthase (GGPPS) regulates non-alcoholic fatty liver disease (NAFLD)-fibrosis progression by determining hepatic glucose/fatty acid preference under high-fat diet conditions.
    Liu J, Jiang S, Zhao Y, Sun Q, Zhang J, Shen D, Wu J, Shen N, Fu X, Sun X, Yu D, Chen J, He J, Shi T, Ding Y, Fang L, Xue B, Li C.
    J Pathol; 2018 Nov 21; 246(3):277-288. PubMed ID: 29971772
    [Abstract] [Full Text] [Related]

  • 13. Sleeve gastrectomy ameliorated high-fat diet (HFD)-induced non-alcoholic fatty liver disease and upregulated the nicotinamide adenine dinucleotide +/ Sirtuin-1 pathway in mice.
    Hua R, Wang GZ, Shen QW, Yang YP, Wang M, Wu M, Shao YK, He M, Zang Y, Yao QY, Zhang ZY.
    Asian J Surg; 2021 Jan 21; 44(1):213-220. PubMed ID: 32712045
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The PDE5 inhibitor udenafil ameliorates nonalcoholic fatty liver disease by improving mitochondrial function.
    Yu HM, Chung HK, Park KS.
    Biochem Biophys Res Commun; 2021 Jun 18; 558():57-63. PubMed ID: 33895552
    [Abstract] [Full Text] [Related]

  • 16. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F, Villani R, Facciorusso A, Vendemiale G, Serviddio G.
    Free Radic Biol Med; 2017 Oct 18; 111():173-185. PubMed ID: 28109892
    [Abstract] [Full Text] [Related]

  • 17. Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression.
    Bellanti F, Villani R, Tamborra R, Blonda M, Iannelli G, di Bello G, Facciorusso A, Poli G, Iuliano L, Avolio C, Vendemiale G, Serviddio G.
    Redox Biol; 2018 May 18; 15():86-96. PubMed ID: 29220698
    [Abstract] [Full Text] [Related]

  • 18. The Alterations of Mitochondrial Function during NAFLD Progression-An Independent Effect of Mitochondrial ROS Production.
    Simões ICM, Amorim R, Teixeira J, Karkucinska-Wieckowska A, Carvalho A, Pereira SP, Simões RF, Szymanska S, Dąbrowski M, Janikiewicz J, Dobrzyń A, Oliveira PJ, Potes Y, Wieckowski MR.
    Int J Mol Sci; 2021 Jun 25; 22(13):. PubMed ID: 34202179
    [Abstract] [Full Text] [Related]

  • 19. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease.
    Xu M, Zheng XM, Jiang F, Qiu WQ.
    J Cell Biochem; 2018 Jul 25; 119(7):5864-5874. PubMed ID: 29575055
    [Abstract] [Full Text] [Related]

  • 20. SARM1 deletion restrains NAFLD induced by high fat diet (HFD) through reducing inflammation, oxidative stress and lipid accumulation.
    Pan ZG, An XS.
    Biochem Biophys Res Commun; 2018 Apr 06; 498(3):416-423. PubMed ID: 29454967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.